We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Advaxis has conducted a pre-investigational new drug (IND) application meeting with the FDA regarding its two planned Phase II studies for its lead product Lovaxin C, a live Listeria vaccine for the treatment of cervical as well as head and neck cancers.
Adventrx Pharmaceuticals announced that it has completed patient enrollment in a Phase IIb clinical trial designed to compare the safety and efficacy of 5-fluorouracil (5-FU) plus CoFactor to 5-FU plus leucovorin in first-line treatment of metastatic colorectal cancer.
Arena Pharmaceuticals announced that an investigational niacin receptor agonist that was being developed under its partnership with Merck is no longer in development for the treatment of atherosclerosis.
Tibotec Pharmaceuticals announced that the expanded access program for TMC125, its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), has opened in the U.S. and will open shortly in Canada and Europe, subject to the necessary approvals.
Spectrum Pharmaceuticals announced positive results from the Phase III satraplatin registrational trial known as SPARC (Satraplatin and Prednisone Against Refractory Cancer).
Orexigen Therapeutics announced that top-line results for the company's lead obesity compound, Contrave, demonstrated significant advantages in weight loss in a 24-week multicenter, placebo-controlled, Phase III trial.
Merck has announced that the European Commission has approved its cervical cancer vaccine, Gardasil (quadrivalent human papillomavirus recombinant vaccine).
The FDA has approved a new use of GlaxoSmithKline's (GSK) anti-seizure drug Lamictal (lamotrigine) Tablets for the treatment of one of the most serious forms of epilepsy -- primary generalized tonic-clonic (PGTC) seizures, also known as "grand mal" seizures.